{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:02:26Z","timestamp":1793257346039,"version":"4.5.0"},"reference-count":115,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Individuals diagnosed with relapsed or refractory large B-cell lymphoma (R\/R LBCL) typically exhibit a dismal prognosis when treated with conventional therapeutic modalities. CD19\u2014targeted chimeric antigen receptor T (CAR-T) cell therapy has brought about a paradigm shift in the treatment paradigm of this disease. Nevertheless, a comprehensive assessment of the efficacy and safety profiles of diverse CAR-T products (e.g., axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)) is imperative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This systematic review aims to systematically summarize and evaluate the efficacy and safety of CAR T-cell therapies for R\/R LBCL through systematic review and meta-analytic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This is a systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>Relevant studies were identified by systematically searching PubMed and Web of Science until November 29, 2023. Cohort studies and clinical trials were incorporated, with the inclusion of single-arm studies. CAR T-cell therapies are involved in tisa-cel, axi-cel, and liso-cel. Proportions and their 95% confidence intervals were calculated using standard meta-analytic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-seven studies were included in meta-analyses, liso-cel demonstrated equivalent overall survival rates (70.3%) to axi-cel (65.6%) at 12\u2009months post-treatment, whereas tisa-cel was 48.0%. Objective response rate for liso-cel was comparable to axi-cel (79.0% vs 76.8%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      <jats:sub>meta-regression<\/jats:sub>\n                      \u2009=\u20090.74), both of which were notably higher than those observed for tisa-cel (58.3%, both\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      <jats:sub>meta-regression<\/jats:sub>\n                      \u2009&lt;\u20090.05). Regarding safety assessments, liso-cel exhibited the lowest cytokine release syndrome rate at 43.0%, followed by tisa-cel at 70.9%, and axi-cel at 87.9%. However, tisa-cel had the lowest incidence of neurologic events (14.9%), in contrast to liso-cel (21.1%) and axi-cel (52.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on the available evidence, liso-cel has shown promising efficacy and a manageable safety profile in patients with R\/R LBCL, when compared to axi-cel and tisa-cel. However, real-world data on liso-cel are limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251407511","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:21:00Z","timestamp":1767432060000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed\/refractory large B-cell lymphoma: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"17","author":[{"given":"Qiang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"},{"name":"Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, 519 Beijing East Road, Nanchang, Jiangxi 330029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-6613","authenticated-orcid":false,"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, 519 Beijing East Road, Nanchang, Jiangxi 330029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.09.006"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.498"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1658"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280805"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.12.015"},{"key":"e_1_3_4_11_2","article-title":"Impact of SCHOLAR-1 criteria on chimeric antigen receptor T cell therapy efficacy in aggressive B lymphoma: a real-world GELTAMO\/GETH study","volume":"29","author":"Bastos-Oreiro M","year":"2023","unstructured":"Bastos-Oreiro M, et al. Impact of SCHOLAR-1 criteria on chimeric antigen receptor T cell therapy efficacy in aggressive B lymphoma: a real-world GELTAMO\/GETH study. Transplant Cell Ther 2023; 29: 747.e1\u2013747.e10.","journal-title":"Transplant Cell Ther"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0164"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18209"},{"key":"e_1_3_4_14_2","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge WA","year":"2022","unstructured":"Bethge WA, et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 2022; 140: 349\u2013358.","journal-title":"Blood"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.855730"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.008"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2113526"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01144-9"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010069"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00268-z"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.018"},{"key":"e_1_3_4_23_2","first-page":"1363","article-title":"Tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma: real-world data from single institute experience","volume":"63","author":"Yagi Y","year":"2022","unstructured":"Yagi Y, et al. Tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma: real-world data from single institute experience. Rinsho Ketsueki 2022; 63: 1363\u20131372.","journal-title":"Rinsho Ketsueki"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3881"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002732"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.005"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005788"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa183"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17550"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238634"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2030475"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1864349"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2095632"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174334"},{"key":"e_1_3_4_35_2","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst M","year":"2021","unstructured":"Ernst M, et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev 2021; 9: Cd013365.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18335"},{"key":"e_1_3_4_37_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page MJ","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12817"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008106"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003531"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000525"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015478"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283162"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02334-w"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.05.004"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5195"},{"key":"e_1_3_4_55_2","article-title":"Quality-adjusted time without symptoms or toxicity: analysis of axicabtagene ciloleucel versus standard of care in patients with relapsed\/refractory large B cell lymphoma","volume":"29","author":"Kersten MJ","year":"2023","unstructured":"Kersten MJ, et al. Quality-adjusted time without symptoms or toxicity: analysis of axicabtagene ciloleucel versus standard of care in patients with relapsed\/refractory large B cell lymphoma. Transplant Cell Ther 2023; 29: 335.e331\u2013335.e338.","journal-title":"Transplant Cell Ther"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001026"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2561"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003503"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.03.013"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3136"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854"},{"key":"e_1_3_4_65_2","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu SS","year":"2023","unstructured":"Neelapu SS, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023; 141: 2307\u20132315.","journal-title":"Blood"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03494-7"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006280"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003848"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2160200"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01756-0"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254045"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0838-y"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006715"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-020-01544-w"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215276"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01960-7"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092411"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17030"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3664"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.007"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.06.005"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-021-00166-5"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1610914"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.19.00086"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000817"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0916"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18831"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109580"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007779"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259"},{"key":"e_1_3_4_97_2","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie C","year":"2023","unstructured":"Roddie C, et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood 2023; 141: 2470\u20132482.","journal-title":"Blood"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33356"},{"key":"e_1_3_4_99_2","volume":"25","author":"CD19\/CD22 Dual-targeted CAR-T therapy active in relapsed\/refractory DLBCL","year":"2020","unstructured":"CD19\/CD22 Dual-targeted CAR-T therapy active in relapsed\/refractory DLBCL. Oncologist 2020; 25(Suppl. 1): S12\u2013S13.","journal-title":"Oncologist"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0075"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011287"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05088-7"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000284"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3686"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.10.011"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01888-z"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0101"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-021-0843-8"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02572-5"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02033-4"},{"key":"e_1_3_4_111_2","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson CA","year":"2022","unstructured":"Jacobson CA, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther 2022; 28: 581.e1\u2013581.e8.","journal-title":"Transplant Cell Ther"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013289"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17527"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01731-4"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4820"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251407511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251407511","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251407511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:06Z","timestamp":1777591086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251407511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":115,"alternative-id":["10.1177\/20406207251407511"],"URL":"https:\/\/doi.org\/10.1177\/20406207251407511","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"20406207251407511"}}